These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32043016)

  • 1. A case of pentosan polysulfate maculopathy originally diagnosed as stargardt disease.
    Vora RA; Patel AP; Yang SS; Melles R
    Am J Ophthalmol Case Rep; 2020 Mar; 17():100604. PubMed ID: 32043016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case Report: Pentosan Polysulfate Sodium Maculopathy Originally Diagnosed as Pattern Macular Dystrophy.
    Case AW; Anderson MJ; Sayomac LE
    Optom Vis Sci; 2021 Jun; 98(6):552-556. PubMed ID: 34039907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanded Clinical Spectrum of Pentosan Polysulfate Maculopathy: A Macula Society Collaborative Study.
    Jain N; Liao A; Garg SJ; Patel SN; Wykoff CC; Yu HJ; London NJS; Khurana RN; Zacks DN;
    Ophthalmol Retina; 2022 Mar; 6(3):219-227. PubMed ID: 34298229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pentosan polysulfate maculopathy.
    Lindeke-Myers A; Hanif AM; Jain N
    Surv Ophthalmol; 2022; 67(1):83-96. PubMed ID: 34000253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MACULAR HOLE IN A PATIENT WITH PENTOSAN POLYSULFATE MACULOPATHY.
    Arora N; Hoyek S; Patel NA
    Retin Cases Brief Rep; 2024 Sep; 18(5):544-548. PubMed ID: 37321232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-Related Macular Degeneration Masquerade: A Review of Pentosan Polysulfate Maculopathy and Implications for Clinical Practice.
    Mukhopadhyay C; Boyce TM; Gehrs KM; Folk JC; Mullins RF; Luo Y; Kreder K; Sohn EH
    Asia Pac J Ophthalmol (Phila); 2022 Mar-Apr 01; 11(2):100-110. PubMed ID: 35533330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nationwide Usage of Pentosan Polysulfate and Practice Patterns of Pentosan Polysulfate Maculopathy Screening in South Korea.
    Kim J; Kwon HY; Kim JH; Ahn SJ
    Ophthalmol Retina; 2024 Mar; 8(3):246-253. PubMed ID: 37832716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cystoid Macular Edema Arising 10 Years After Cessation of Pentosan Polysulfate Sodium Successfully Treated With Bevacizumab.
    Szelog JT; Shah NS; Camejo MD
    J Vitreoretin Dis; 2023; 7(1):83-86. PubMed ID: 37008392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pentosan Polysulfate Maculopathy With 13 Years of Follow-up Imaging.
    Pinto AM; Jain N; Gupta RR
    J Vitreoretin Dis; 2024; 8(3):325-333. PubMed ID: 38770071
    [No Abstract]   [Full Text] [Related]  

  • 10. Prevalence and Dose Dependency Analysis of Pentosan Polysulfate Sodium Maculopathy.
    Philip AM; Wannamaker KW; Miller DM
    Ophthalmic Epidemiol; 2023 Feb; 30(1):82-87. PubMed ID: 35081852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type 3 macular neovascularization in a patient with pentosan polysulfate maculopathy.
    Bousquet E; Lee BA; Santina A; Sadda S; Sarraf D
    Am J Ophthalmol Case Rep; 2023 Mar; 29():101771. PubMed ID: 36561881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. POTENTIAL NEW-ONSET CLINICALLY DETECTABLE PENTOSAN POLYSULFATE MACULOPATHY YEARS AFTER DRUG CESSATION.
    Barnett JM; Jain N
    Retin Cases Brief Rep; 2022 Nov; 16(6):724-726. PubMed ID: 33229920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PENTOSAN POLYSULFATE SODIUM (ELMIRON) MACULOPATHY: A Genetic Perspective.
    Kalaw FGP; Ignacio JCI; Wu CY; Ferreyra H; Nudleman E; Baxter SL; Freeman WR; Borooah S
    Retina; 2023 Jul; 43(7):1174-1181. PubMed ID: 36996461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pentosan Polysulfate Maculopathy versus Inherited Macular Dystrophies: Comparative Assessment with Multimodal Imaging.
    Barnes AC; Hanif AM; Jain N
    Ophthalmol Retina; 2020 Dec; 4(12):1196-1201. PubMed ID: 32446908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An unusual case of rapid resolution of bilateral vitelliform deposits after discontinuation of pentosan polysulfate sodium.
    Kalaw FGP; Scott NL; Borooah S
    Am J Ophthalmol Case Rep; 2023 Dec; 32():101875. PubMed ID: 37645698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pentosan Polysulfate Sodium Exposure and Drug-Induced Maculopathy in Commercially Insured Patients in the United States.
    Ludwig CA; Vail D; Callaway NF; Pasricha MV; Moshfeghi DM
    Ophthalmology; 2020 Apr; 127(4):535-543. PubMed ID: 31899034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maculopathy Secondary to Pentosan Polysulfate Use: A Single-Center Experience.
    Kalbag NS; Maganti N; Lyon AT; Mirza RG
    Clin Ophthalmol; 2021; 15():513-519. PubMed ID: 33603329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease Course in Patients With Pentosan Polysulfate Sodium-Associated Maculopathy After Drug Cessation.
    Shah R; Simonett JM; Lyons RJ; Rao RC; Pennesi ME; Jain N
    JAMA Ophthalmol; 2020 Aug; 138(8):894-900. PubMed ID: 32644147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pentosan polysulfate maculopathy versus age-related macular degeneration: comparative assessment with multimodal imaging.
    Christiansen JS; Barnes AC; Berry DE; Jain N
    Can J Ophthalmol; 2022 Feb; 57(1):16-22. PubMed ID: 33722504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VISUAL AND ANATOMICAL CHANGES AFTER DRUG CESSATION IN PENTOSAN POLYSULFATE SODIUM-ASSOCIATED MACULOPATHY.
    Gupta PR; Grewal DS
    Retin Cases Brief Rep; 2023 Sep; 17(5):507-510. PubMed ID: 37643033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.